• Press Release

Scientists Reveal New Findings for Reversing Early and Late Atherosclerosis

Icahn School of Medicine at Mount Sinai study suggests early-stage atherosclerosis is reversible, and identifies new genetic targets for fighting advanced atherosclerosis.

  • New York
  • (February 28, 2014)

Research at Icahn School of Medicine at Mount Sinai has led to important new discoveries about the process behind regression of atherosclerosis, the main underlying cause of heart attack and stroke. In the paper published today in PLoS Genetics, scientists from Mount Sinai and the Karolinska Institute in Sweden studied how atherosclerosis is reversed by lowering LDL cholesterol in mice. Remarkably, early-stage atherosclerotic plaques were entirely reversible, while more advanced plaques developed a resistance to low LDL cholesterol therapy.

In addition, the researchers also identified gene networks within atherosclerotic plaques leading to the discovery of new molecular targets that could help improve responsiveness to LDL-cholesterol therapy in advanced atherosclerosis.

Atherosclerosis, the hardening of the arteries due to the buildup of cholesterol-rich plaques in the walls of arteries, is the primary cause of heart attacks and strokes, which together account for more than half of all deaths worldwide. Advanced atherosclerosis is dangerous and underlies most cases of heart attack or stroke. Scientists have been searching for ways to prevent early-stage atherosclerosis from progressing to the more dangerous, advanced stage to improve outcomes for those patients at risk of coronary or carotid artery disease (CAD).

"The vascular process that responds to plasma cholesterol lowering therapy was not previously well understood, so our aim in this study was to establish a clearer picture of this function," said Johan Björkegren, MD, PhD, co-lead study author and Professor of Genetics and Genomic Sciences at Icahn School of Medicine at Mount Sinai. "Our discovery that early-stage atherosclerosis can regress completely, whereas later-stage atherosclerosis is resistant to treatment, suggests that individuals at increased CAD risk would benefit greatly from early prevention using lipid-lowering drugs like statins."

These new study findings add support to the 2013 American Heart Association guidelines proposing that healthy people at increased risk for CAD shall receive statin therapies even if their LDL cholesterol levels are only mildly elevated in that statin therapy to people with early lesions might be more effective to reverse atherosclerosis than administrating these drugs to patients with more advanced forms of arterial plaques.

In the study, scientists also identified gene networks responsible for the effect of LDL-cholesterol lowering on atherosclerosis regression. In mice with early-stage atherosclerosis, a key driver gene in the network known as PPARG was found to be involved in causing the complete regression. In mature and advanced cases, different key driver genes in the network proved to be most influential in controlling the regression of atherosclerosis: MLL5 in mature cases and SRSF10/XRN2 in advanced cases.

The study authors note that these three key genetic drivers may serve as new targets to improve regression of more advanced forms of atherosclerosis.

"It is our hope that the genetic targets we identified in more advanced atherosclerosis will be useful in developing new therapies to reverse dangerous advanced arterial plaque disease," states Dr. Björkegren.

The new study, entitled "Plasma Cholesterol–Induced Lesion Networks Activated before Regression of Early, Mature, and Advanced Atherosclerosis," was published in PLoS Genetics and is available here: http://www.plosgenetics.org/doi/pgen.1004201

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.